Tag: cdmo

cdmo

Latest News

Samsung Biologics' headquarters in Songdo, Incheon, is seen in a photo taken on June 28.

Samsung Biologics plans 3 trillion won capital increase to fund PolyPeptide Group deal

The rights offering aims to accelerate the company’s push to become a world-leading contract development and manufacturing organization, Samsung Biologics said.

2026.8.28

CHA Biotech's U.S. arm launches CDMO platform, bags first client

New manufacturing system shortens gene therapy development timelines and improves client collaboration.

2026.6.17

Samsung Biologics reports record-breaking $1.1 billion in revenue in Q3

Samsung Biologics reported record earnings for the third quarter, posting more than 1.6 trillion won ($1.1 billion) in revenue, driven by large-scale contract wins with global pharmaceutical firms and strong sales of biosimilars.

2025.10.28

Matica Biotechnology's plant in College Station, Texas [CHA BIOTECH]

Cha Biotech's U.S. CDMO arm inks vector deal with Cirsium

Matica Biotechnology, the U.S. contract development and manufacturing organization arm of Cha Biotech, announced Tuesday that it signed an agreement with Cirsium Biosciences to produce the California-based firm's vectors.

2025.9.9

The Samsung Biologics headquarters in Incheon is seen on May 31, 2023. [JOONGANG ILBO]

Samsung to spin off Biologics, put biosimilar subsidiary in holding company to boost CDMO

Samsung Group is striving to strengthen its investments and research and development (R&D) in the bio industry by establishing an intermediate holding company for its bio affiliates, spinning off Samsung Biologics.

2025.5.23

Syringes used in injectable medicines are being filled in sterile conditions in Wuxi City, China, in 2023. [WUXI BIOLOGICS/REUTERS]

As U.S.-China biotech tensions rise, Korea holds its breath

The United States' proposed Biosecure Act has created a volatile market for Chinese firms but has potential benefits for the Korean pharmaceutical industry.

2024.2.13

Samsung Biologics CEO John Rim speaks during the annual 42nd J.P. Morgan Healthcare Conference at the main Grand Ballroom in the Westin St. Francis Hotel in San Francisco, California. [SAMSUNG BIOLOGICS]

Samsung Biologics posts record profits after string of contract wins

Samsung Biologics, a biopharmaceutical contract manufacturer, posted an all-time-high operating profit of 1.11 trillion won ($829.3 billion) last year, up 13.22 percent on year, according to the company’s regulatory filing Wednesday.

2024.1.24

The annual J.P. Morgan Healthcare Conference will be held in San Francisco from Jan. 8 to 11, with six Korean companies set to deliver presentations at the event. [SCREEN CAPTURE]

Samsung Biologics, Celltrion to attend J.P. Morgan Healthcare Conference in San Francisco

Korean pharmaceutical companies including Samsung Biologics and Celltrion are scheduled to attend the upcoming J.P. Morgan Healthcare Conference in San Francisco from Jan. 8 to 11.

2023.12.26

A digital render of Samsung Biologics' Plant 5 in Songdo, Incheon [SAMSUNG BIOLOGICS]

Samsung Biologics orders hit 3 trillion won in historic milestone

Samsung Biologics has secured five biomanufacturing contracts, bringing the total of its 2023 orders to over 3 trillion won for the first time since its foundation.

2023.11.28

Lotte Biologics CEO Richard Lee speaks during a press event held in Barcelona, where the CPHI Worldwide 2023 took place, on Wednesday. [LOTTE BIOLOGICS]

Lotte Biologics looks to go public by 2027-28, build third plant

BARCELONA, Spain — Lotte Biologics, a biopharmaceutical contract manufacturer, aims to go public by around 2027 to 2028, according to its CEO.

2023.10.30